Our results with the mutants agree with Gontarewicz et al., who reported that PHA-739358 was effective against imatinib-resistant Bcr/Abl mutants including those with the T315I mutation in human and mouse leukemia cell lines as well as in CD34+ cells from an imatinib-resistant CML patient [24]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.